Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence.
about
Patterns and predictors of osteoporosis medication discontinuation and switching among Medicare beneficiariesSeven years' experience with alendronate in postmenopausal Japanese women with osteoporosis.Improving management of patients with advanced cancerInterventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group.Measuring and improving adherence to osteoporosis pharmacotherapy.Methods to examine the impact of compliance to osteoporosis pharmacotherapy on fracture risk: systematic review and recommendationsAdherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors.A phase IV, two-armed, randomized, cross-over study comparing compliance with once-a-month administration of vitamin D3 to compliance with daily administration of a fixed-dose combination of vitamin D3 and calcium during two 6-month periods.Nominal group technique to select attributes for discrete choice experiments: an example for drug treatment choice in osteoporosis.Predictors of very low adherence with medications for osteoporosis: towards development of a clinical prediction ruleCost-effectiveness of strontium ranelate in the treatment of male osteoporosis.Evaluation of persistence and adherence to teriparatide treatment in patients affected by severe osteoporosis (PATT): a multicenter observational real life study.Reactive oxygen species are required for zoledronic acid-induced apoptosis in osteoclast precursors and mature osteoclast-like cells.Overcoming problems with adherence to osteoporosis medication.Partial adherence: a new perspective on health economic assessment in osteoporosis.Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporotic women.Comparison of prescribing and adherence patterns of anti-osteoporotic medications post-admission for fragility type fracture in an urban teaching hospital and a rural teaching hospital in Ireland between 2005 and 2008.The potential impact of new effervescent alendronate formulation on compliance and persistence in osteoporosis treatment.A systematic review of cost-effectiveness analyses of drugs for postmenopausal osteoporosis.Design of a pragmatic approach to evaluate the effectiveness of concurrent treatment for the prevention of osteoporotic fractures: rationale, aims and organization of a Japanese Osteoporosis Intervention Trial (JOINT) initiated by the Research GroupRole of Side Effects, Physician Involvement, and Patient Perception in Non-Adherence with Oral Bisphosphonates.Fractures and mortality in relation to different osteoporosis treatments.Influence of refill adherence method when comparing level of adherence for different dosing regimens.GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates.Adherence to osteoporosis medications amongst Singaporean patients.Three-year experience with risedronate therapy for patients with an increased fracture risk: assessment of proximal femoral bone density and geometry by DXA.Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium.A Randomized Study to Compare a Monthly to a Daily Administration of Vitamin D₃ Supplementation.
P2860
Q33617272-D3B61071-9EB1-42E6-83EC-E572BB11C06FQ33817802-F8733184-79A5-4ECA-BD8F-03F1D86755D7Q34413634-C1B1C84D-34DC-42F1-AD03-F6C024EAD5D4Q34699332-B363B411-4466-4668-A276-AAFB4D6766ACQ35177690-235A175E-2844-4918-9B97-37A918DB685EQ35693057-C95E6A5F-60E7-4333-B2D0-2BCF286280FAQ35751984-44240592-2D2A-48D4-8A76-0FADACB44CE1Q36309326-194564BF-4BE3-46CC-ADB8-6E7BAB6FC15EQ36610799-4778FEDB-FB58-49C5-915C-37A9D7C60379Q36830647-64E23D02-607B-442F-A443-73076AD7F1D6Q36997684-6ECABB89-556F-4B6A-A9B6-01A81528DA53Q37008062-4B399ECC-4CCC-4823-8A1B-069AB6B573CDQ37692256-AE256FED-9DCB-494B-8322-3E05B0BC0E2FQ37820680-3096B101-D916-4554-98F7-FB7A492940CAQ37880657-7B81202C-AE2F-4340-87C6-71DC3742C580Q38080911-D0847FCE-4590-4CE6-95D2-32CF26FD899DQ38088664-24F34204-6593-4E2E-82FC-52C9AF0E8F5DQ38226482-59414B05-E51F-4C26-84E3-090883827AA0Q38265934-C751B29B-9C63-47E5-BC9A-DA2D0A4F0CD7Q39874235-AD896090-F354-488B-A082-7AB18CCCA727Q40688871-B05E4798-6D4A-4BA9-9232-DE5A311418BDQ43577539-9C281544-866D-4D89-9A08-7D3D3B7F6857Q44131390-77AC88F3-ACA6-4BFA-B278-F2491CCD42AFQ44452724-359246F7-A1D8-4796-B06C-61044EAFDA3BQ44541046-B21B715B-D6E3-488B-A05E-2729AA0533BDQ44745930-67A8D0CF-5FEC-4A36-B55B-03BF715BD726Q45856669-F505ABE8-3311-47C4-95CD-1FD266E5B248Q55482427-645F16B5-800E-417D-8533-59048497C3B6
P2860
Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Poor adherence to oral bisphos ...... ces: a review of the evidence.
@en
Poor adherence to oral bisphos ...... ces: a review of the evidence.
@nl
type
label
Poor adherence to oral bisphos ...... ces: a review of the evidence.
@en
Poor adherence to oral bisphos ...... ces: a review of the evidence.
@nl
prefLabel
Poor adherence to oral bisphos ...... ces: a review of the evidence.
@en
Poor adherence to oral bisphos ...... ces: a review of the evidence.
@nl
P2860
P1476
Poor adherence to oral bisphos ...... ces: a review of the evidence.
@en
P2093
Michaël Hiligsmann
Véronique Rabenda
P2860
P304
P356
10.1517/14656560903140533
P407
P577
2009-10-01T00:00:00Z